

# SENATE BILL No. 1113

October 18, 2016, Introduced by Senators SCHUITMAKER, O'BRIEN, PROOS and MARLEAU and referred to the Committee on Health Policy.

A bill to amend 1978 PA 368, entitled  
"Public health code,"  
(MCL 333.1101 to 333.25211) by adding sections 17019 and 17519.

## THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

- 1        SEC. 17019. (1) BEGINNING JANUARY 1, 2018, A PHYSICIAN WHO  
2        SPECIALIZES IN PRIMARY CARE SHALL INCLUDE ON THE PHYSICIAN'S  
3        PATIENT INTAKE FORM QUESTIONS THAT ARE ENDORSED BY THE UNITED  
4        STATES PREVENTATIVE SERVICE TASK FORCE OR THE NATIONAL  
5        COMPREHENSIVE CANCER NETWORK AND ARE DESIGNED TO IDENTIFY A PATIENT  
6        WHO HAS A FAMILY HISTORY THAT MAY BE ASSOCIATED WITH AN INCREASED  
7        RISK OF HEREDITARY BREAST OR OVARIAN CANCER.  
8        (2) IF A PATIENT'S RESPONSE TO 1 OR MORE OF THE QUESTIONS

1 DESCRIBED IN SUBSECTION (1) INDICATES A FAMILY HISTORY THAT MAY BE  
2 ASSOCIATED WITH AN INCREASED RISK OF HEREDITARY BREAST OR OVARIAN  
3 CANCER, THE PHYSICIAN SHALL PROVIDE THE PATIENT WITH INFORMATION ON  
4 GENETIC COUNSELING FOR THE PURPOSE OF DETERMINING WHETHER GENETIC  
5 TESTING FOR MUTATIONS IN GENES ASSOCIATED WITH BREAST AND OVARIAN  
6 CANCER IS APPROPRIATE FOR THE PATIENT.

7 SEC. 17519. (1) BEGINNING JANUARY 1, 2018, A PHYSICIAN WHO  
8 SPECIALIZES IN PRIMARY CARE SHALL INCLUDE ON THE PHYSICIAN'S  
9 PATIENT INTAKE FORM QUESTIONS THAT ARE ENDORSED BY THE UNITED  
10 STATES PREVENTATIVE SERVICE TASK FORCE OR THE NATIONAL  
11 COMPREHENSIVE CANCER NETWORK AND ARE DESIGNED TO IDENTIFY A PATIENT  
12 WHO HAS A FAMILY HISTORY THAT MAY BE ASSOCIATED WITH AN INCREASED  
13 RISK OF HEREDITARY BREAST OR OVARIAN CANCER.

14 (2) IF A PATIENT'S RESPONSE TO 1 OR MORE OF THE QUESTIONS  
15 DESCRIBED IN SUBSECTION (1) INDICATES A FAMILY HISTORY THAT MAY BE  
16 ASSOCIATED WITH AN INCREASED RISK OF HEREDITARY BREAST OR OVARIAN  
17 CANCER, THE PHYSICIAN SHALL PROVIDE THE PATIENT WITH INFORMATION ON  
18 GENETIC COUNSELING FOR THE PURPOSE OF DETERMINING WHETHER GENETIC  
19 TESTING FOR MUTATIONS IN GENES ASSOCIATED WITH BREAST AND OVARIAN  
20 CANCER IS APPROPRIATE FOR THE PATIENT.

21 Enacting section 1. This amendatory act takes effect 90 days  
22 after the date it is enacted into law.